1. Introduction
===============

Numerous epidemiological studies have shown that the prevalence of resistant hypertension, which is defined as clinic systolic and/or diastolic blood pressure (SBP/DBP) ≥ 140/90 in spite of using ≥ 3 different classes of antihypertensive medications, is gradually increasing.^\[[@R1]--[@R4]\]^ Notably, sustained BP elevation contributes to target organs damage, cardiovascular and renal events and premature death.^\[[@R5]--[@R7]\]^ Therefore, BP control is essential for preventing resistant hypertension development and reducing cardiovascular events.^\[[@R8]\]^

According to the 2008 American Heart Association Scientific Statement,^\[[@R1]\]^ thiazide diuretic such as hydrochlorothiazide (HCTZ) is recommended as the first line medication for resistant hypertension management. Spironolactone, a potassium-sparing diuretic, is recommended as the fourth line medication if BP could not control despite using optimal doses of 3 different classes of antihypertensive medications.^\[[@R1]\]^

In recent 2 decades, accumulating evidence has revealed that arterial stiffness is an independent risk factor of hypertension, coronary heart disease and cerebrovascular disease. Blood pressure elevation leads to arterial stiffness, which in turn makes BP difficult to control.^\[[@R9]--[@R11]\]^ Therefore, it is reasonable to anticipate that improved arterial stiffness would be beneficial for BP control and resistant hypertension prevention. Prior experimental studies showed that aldosterone antagonist has potent effects on improving vascular fibrosis via inhibiting fibroblast proliferation and improving endothelial function. Clinical studies also suggested that arterial stiffness could be improved by salt restriction and aldosterone antagonist therapy in hypertensive patients.^\[[@R12],[@R13]\]^

We therefore conducted a prospective study to evaluate the differences in BP control and arterial stiffness improvement between HCTZ versus spironolactone treatment in patients with uncontrolled hypertension.

2. Methods
==========

2.1. Study participants
-----------------------

Study participants were enrolled after informed consent was obtained and current study was approved by the Research Ethic Committee of The Third People\'s Hospital of Huizhou. Included criteria were as follows: hypertensive patients with clinic SBP and/or DBP ≥ 140/90 mm Hg and were treating with optimal doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and calcium channel blocker (CCB), and without contraindications to HCTZ or spironolactone treatment. Excluded criteria were as follows: documented secondary hypertension, pregnant women, have myocardial infarction, ischemic stroke, atrial fibrillation or congestive heart failure in the past 6 months. All the performances were in accordance to the Declaration of Helsinki.

2.2. Medications prescription
-----------------------------

Participants were prescribed HCTZ (25 mg/qd) if the last digit of their telephone numbers was odd, or prescribed spironolactone (25 mg/qd) if the last digit of their telephone numbers was even. In specific, HCTZ was prescribed as a single pill rather than a combined medication. The duration of treatment was 4 weeks and other antihypertensive medications were without changes. During the periods of active treatment, participants were follow-up by investigator every 2 weeks by telephone and no side effects were reported.

2.3. Data collection
--------------------

Demographic data including age, gender, smoking status, previous medical history, and current medications usage were collected using self-administered questionnaire; anthropometric data including body weight, height, SBP/DBP, and heart rate at rest were measured by investigators in accordance to guideline recommendation.^\[[@R14]\]^ In brief, BP was measured 3 times and the last 2 BP readings were averaged to obtain the clinic BP. Body mass index (BMI) was calculated by body weight in kilogram divided by height in squared meter. Overnight fasting venous blood was drawn for electrolytes, creatinine, fasting plasma glucose (FPG), lipid profiles, uric acid, and C-reactive protein (CRP) measurements.

2.4. Arterial stiffness measurement
-----------------------------------

At baseline and after 4 weeks of HCTZ or spironolactone treatment, carotid-femoral pulse wave velocity (cf-PWV) was assessed to determine arterial stiffness, and all the procedures were performed in accordance to guideline recommendation^\[[@R15]\]^ by 2 independent investigators who were blinded to the treatment allocation (Atcor Medical Blood Pressure Analysis System, Sydney Australia). Measurement was done at the right common carotid and common femoral arteries and the distance between these 2 points were calculated by a tape, and the travel time of pulse wave between these 2 points were measured and calculated by the device automatically.

2.5. Statistical analysis
-------------------------

Continuous variables were presented as mean ± SD and categorical variables were presented as number and percentages of cases. Student *t* test for continuous variables comparison and the chi-square or Fisher exact test for categorical variables comparison were conducted. Pearson or Spearman correlation analysis was used to evaluate the relationship between cf-PWV and age, male gender, BMI, SBP, uric acid, CRP, diabetes mellitus, statins, spironolactone, and HCTZ after 4 weeks' treatment. Logistic regression analysis was used to evaluation the association between per 1-SD standardized increase cf-PWV and incidence of resistant hypertension. Covariates were entered in a stepwise model. Potential interaction between cf-PWV and HTCZ and spironolactone was evaluated and no significant interaction was observed. Statistical analyze were computed using SPSS 17.0 (SPSS Inc, Chicago, IL). All statistical tests were two-sided and considered statistically significant when *P \< *.05.

3. Results
==========

3.1. Baseline characteristics
-----------------------------

From January of 2015 to June of 2017, we had totally screened 609 uncontrolled hypertensive patients in our outpatient clinic. Among them, 3 had secondary hypertension, 2 pregnant women, 11 had myocardial infarction, 8 ischemic stroke, 11 atrial fibrillation, and 8 congestive heart failure in the past 6 months. Finally, a total of 566 patients were included into final analysis. The mean age was 55.6 ± 13.7 years, and male participants accounted for nearly 58%. Nearly 33%, 28%, and 17% of participants had cigarette smoking, type 2 diabetes mellitus, and angiographically diagnosed coronary heart disease, respectively. The mean SBP and DBP were 143 ± 13 mm Hg and 94 ± 10 mm Hg, respectively. The mean cf-PWV was 9.9 ± 1.2 m/s, with arterial stiffness prevalence was 32% in accordance to the cutoff value of 10 m/s as indicated by guideline.^\[[@R15]\]^ Other baseline characteristics were presented in Table [1](#T1){ref-type="table"}.
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3.2. Baseline characteristics comparisons between HCTZ and spironolactone groups
--------------------------------------------------------------------------------

A slightly higher proportion of participants were prescribed HCTZ versus spironolactone (52% versus 48%). As presented in Table [1](#T1){ref-type="table"}, no significant differences in baseline characteristics were observed between HCTZ and spironolactone groups.

3.3. Baseline medications comparisons between HCTZ and spironolactone groups
----------------------------------------------------------------------------

Baseline medications usages were compared between HCTZ and spironolactone groups. As shown in Table [2](#T2){ref-type="table"}, no significant differences in medications usage were observed, except for higher percentage of statins usage in HCTZ group versus spironolactone group.
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Comparisons of medications between HCTZ and spironolactone groups.
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3.4. Comparisons of BP and cf-PWV after 4 weeks' treatment
----------------------------------------------------------

As presented in Table [3](#T3){ref-type="table"}, after 4 weeks' treatment, SBP was reduced more profoundly in spironolactone group versus HCTZ group (130 ± 10 mm Hg vs 134 ± 9 mm, *P \< *.05). In addition, cf-PWV was also reduced more profoundly in spironolactone group versus HCTZ group (9.6 ± 1.3 mm Hg vs 9.9 ± 1.4 mm, *P \< *.05). Although the percentage of participants developing resistant hypertension was lower in spironolactone group versus HCTZ group (41% vs 45%), but the difference did not achieve statistical significance (*P* = .063).
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![](medi-97-e0500-g003)

3.5. Pearson and Spearman correlation analysis
----------------------------------------------

After 4 weeks' treatment, Pearson and Spearman correlation analysis was performed to evaluate the relationship between cf-PWV and parameters of interest. As presented in Table [4](#T4){ref-type="table"}, age, type 2 diabetes mellitus, and HCTZ were all positively correlated with cf-PWV, while spironolactone was negatively correlated with cf-PWV.
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Correlation between cf-PWV and parameters of interest.
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3.6. Logistic regression analysis
---------------------------------

As showed in Table [5](#T5){ref-type="table"}, in unadjusted model, increased cf-PWV was significantly associated with a 92% higher incidence of resistant hypertension. With stepwise adjustment for potential confounding factors, the hazard ratio was gradually reduced. In model 4, after additionally adjusted for HCTZ, no significant change of hazard ratio was observed; nevertheless, in model 5, after additionally adjusted for spironolactone, the hazard ratio was substantially reduced and no significant association between cf-PWV and incident resistant hypertension was observed, indicating that the adverse effect of arterial stiffness on resistant hypertension development might be reversed by spironolactone treatment.
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Logistic regression analyses of cf-PWV and incidence of resistant hypertension.
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4. Discussion
=============

The present study has the following principal findings. First, in uncontrolled hypertensive patients with optimal doses of ACEI/ARB and CCB treatment, adding spironolactone is better than adding HCTZ for SBP and cf-PWV reduction. Second, correlation analysis suggests that HCTZ is positively correlated with cf-PWV while spironolactone is negatively correlated with cf-PWV. Third, the detrimental effect of arterial stiffness on resistant hypertension development may be reversed by spironolactone treatment. Future randomized double-blinded controlled trials are warranted to evaluate whether long-term spironolactone treatment could improve arterial stiffness, decrease incident resistant hypertension, and improve cardiovascular prognosis.

Numerous cross-sectional studies reveal that patients with resistant hypertension have higher prevalence of co-morbidities such as coronary heart disease, ischemic stroke, congestive heart failure, and chronic kidney disease.^\[[@R16]\]^ In addition, prospective cohort studies also indicate that resistant hypertension is an independent risk factor of cardiovascular and renal events.^\[[@R3],[@R17],[@R18]\]^ Therefore, it is clinically relevant to prevent resistant hypertension development. Arterial stiffness, featured by vascular fibrosis and endothelial dysfunction, is a major risk factor of hypertension.^\[[@R9],[@R10]\]^ Moreover, hypertension per se could lead to arterial stiffening, which in turn causes BP elevation.^\[[@R11]\]^ Therefore, one may anticipate that improved arterial stiffness would be beneficial for BP control. Indeed, prior studies showed that spironolactone could reduce BP via improving arterial stiffness.^\[[@R22]\]^

Thiazide diuretic is the first line medication for resistant hypertension treatment.^\[[@R1]\]^ Nevertheless, some studies have revealed that thiazide diuretic has unwanted effects such as impairing glucose metabolism, inducing insulin resistance, and enhancing sympathetic nerve activity.^\[[@R19],[@R20]\]^ These pathological alterations could result in arterial stiffness. In contrast, besides lowering BP, aldosterone antagonist has documented pleiotropic effects including improving endothelial function, anti-inflammation and antifibrosis.^\[[@R21]--[@R23]\]^ Therefore, one may anticipate that spironolactone treatment would be better than HCTZ for arterial stiffness improvement and BP control. Results from the present study support this hypothesis. As presented in Table [3](#T3){ref-type="table"}, after 4 weeks' spironolactone treatment, SBP and cf-PWV were reduced more profoundly than HCTZ. In addition, correlation analysis indicates that HCTZ usage correlates with arterial stiffness while spironolactone treatment may improve arterial stiffness. In addition, results from logistic regression analysis further strengthen these findings. As shown in logistic regression model, after adjusted for spironolactone, the independent association of arterial stiffness and incident resistant hypertension was attenuated to nonsignificant. A prior prospective cross-over study also indicated that in elderly uncontrolled hypertensive patients with concurrently amlodipine and candesartan treatment.^\[[@R24]\]^ spironolactone treatment seemed to be better than chlorthalidone as add-on treatment due to its effect on endothelial protection and inflammation amelioration. However, one should be cautious that the combination of ACEI or ARB and spironolactone increases the risk of hyperkalemia and patients should be closely monitored serum potassium level.

The strength of current study is the prospective design and a large sample size. The limitations of current study include the followings: first, it was not a truly randomized and double-blinded design, and the duration of follow-up was only 4 weeks. Second, thiazide diuretic such as chlorthalidone has more potent efficacy than HCTZ, and whether chlorthalidone therapy would have differing effects on BP control and arterial stiffness improvement compared to HCTZ is unknown. Since in mainland of China is lacking chlorthalidone, future study in investigating this hypothesis is warranted in areas where chlorthalidone is available. Third, peripheral arterial disease may alter blood pressure and cf-PWV values. However, our current study did not evaluate the potential peripheral arterial disease and therefore we could not adjust for the potential covariates in the regression model. To our knowledge, concurrent peripheral arterial disease indeed would influence cf-PWV change and blood pressure measurement. In future study, it is warranted to evaluate peripheral arterial disease and to investigate whether and to what extent peripheral arterial disease will influence cf-PWV and blood pressure change

5. Conclusion
=============

In summary, our present study indicates that in uncontrolled hypertensive patients, adding spironolactone appears to be better than HCTZ for SBP control, cf-PWV reduction and prevention of resistant hypertension development.
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